<DOC>
	<DOCNO>NCT01623453</DOCNO>
	<brief_summary>This open follow-up clinical trial evaluate sustain efficacy safety ANTG-ASC injection 4 month ( 6 month final dose injection ) Phase II clinical trial .</brief_summary>
	<brief_title>Follow-up Study Autologous Adipose-derived Stem Cells ( ANTG-ASC ) Complex Fistula ( ANTG-ASC-211 )</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<criteria>patient participate ANTGASC210 clinical trial patient complete closure week 8 last injection ANTGASC210 trial patient submit write informed consent able obey requirement trial patient history variant Creutzfeldt Jacobs disease related diseases patient allergic anesthetic , bovine derive protein fibrin glue patient autoimmune disease patient infectious disease hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) patient symptom septicemia active tuberculosis ( contain tuberculosis anus rectum ) patient pregnant breast feeding patient willing use effective contraceptive method study patient inflammatory Bowel disease patient sensitive fibrin glue patient clinically relevant history abuse alcohol drug , habitual smoker ( smoke 20 cigarette day ) patient able understand objective study comply study requirement patient consider significant disease impact study investigator patient consider suitable study investigator patient history surgery malignant tumor within last five year ( except carcinoma situ ) patient multisystemic wasting syndrome ( tuberculosis , Diabetes , Thyroid disorder , tumor , etc . ) patient take cytotoxic drug ( immunosuppressant , corticosteroid , cytotoxic chemotherapy , anticoagulant , etc . ) longterm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>crohn 's disease</keyword>
	<keyword>fistula</keyword>
	<keyword>complex</keyword>
</DOC>